Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jun;65(6):934–941. doi: 10.1038/bjc.1992.196

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.

PMCID: PMC1977779  PMID: 1377484

Abstract

Two policies of palliative thoracic radiotherapy for NSCLC have been compared in a randomised multicentre controlled trial aimed at simplifying the palliative treatment of patients with poor performance status. A total of 235 patients were entered. They had inoperable, microscopically confirmed disease, too advanced for 'curative' radiotherapy. Their main symptoms were related to the primary intrathoracic tumour even if metastases were present, and they had a poor performance status. Patients were allocated at random to regimens of either 17 Gy given in two fractions of 8.5 Gy 1 week apart (F2 regimen, 117 patients), or a single fraction of 10 Gy (F1 regimen, 118 patients). Two patients (one in each group) were excluded from all analyses because they were found to have had previously treated malignant disease and had been admitted in error. On admission, 95% of the 233 eligible patients had cough, 47% haemoptysis, 59% chest pain, 64% anorexia, and 16% dysphagia. As assessed by the clinicians, these symptoms were palliated in high proportions of patients, ranging in the F2 group from 48% for cough to 75% for haemoptysis, and in the F1 group from 55% for anorexia to 72% for haemoptysis and chest pain. For all five symptoms the median duration of palliation was 50% or more of survival. All these results were similar in the two treatment groups. In contrast, on daily assessment by the patients using a diary card, those treated with the F2 regimen experienced substantially more dysphagia, which was recorded in 56% of the patients compared with 23% in the F1 group (difference 33%: 95% confidence interval 17-48%). The median survival from randomisation was 100 days in the F2 group and 122 days in the F1 group. The F1 regimen, as it requires only a single attendance for treatment, is recommended as a palliative regimen for patients with inoperable NSCLC and a poor performance status.

Full text

PDF
934

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carroll M., Morgan S. A., Yarnold J. R., Hill J. M., Wright N. M. Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol. 1986 Nov;22(11):1353–1356. doi: 10.1016/0277-5379(86)90144-6. [DOI] [PubMed] [Google Scholar]
  2. Fayers P. M., Bleehen N. M., Girling D. J., Stephens R. J. Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer. 1991 Aug;64(2):299–306. doi: 10.1038/bjc.1991.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ganz P. A., Figlin R. A., Haskell C. M., La Soto N., Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer. 1989 Apr 1;63(7):1271–1278. doi: 10.1002/1097-0142(19890401)63:7<1271::aid-cncr2820630707>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  4. Ganz P. A., Haskell C. M., Figlin R. A., La Soto N., Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer. Cancer. 1988 Feb 15;61(4):849–856. doi: 10.1002/1097-0142(19880215)61:4<849::aid-cncr2820610435>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  5. Geddes D. M., Dones L., Hill E., Law K., Harper P. G., Spiro S. G., Tobias J. S., Souhami R. L. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer. 1990 Apr;26(4):484–492. doi: 10.1016/0277-5379(90)90022-l. [DOI] [PubMed] [Google Scholar]
  6. Macbeth F. R., Bolger J. Palliative radiotherapy for bronchial carcinoma: science or art? Clin Oncol (R Coll Radiol) 1991 Sep;3(5):245–246. doi: 10.1016/s0936-6555(05)80870-2. [DOI] [PubMed] [Google Scholar]
  7. Mulshine J. L., Glatstein E., Ruckdeschel J. C. Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov;4(11):1704–1715. doi: 10.1200/JCO.1986.4.11.1704. [DOI] [PubMed] [Google Scholar]
  8. Slevin M. L., Plant H., Lynch D., Drinkwater J., Gregory W. M. Who should measure quality of life, the doctor or the patient? Br J Cancer. 1988 Jan;57(1):109–112. doi: 10.1038/bjc.1988.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x. [DOI] [PubMed] [Google Scholar]
  10. de Haes J. C., van Oostrom M. A., Welvaart K. The effect of radical and conserving surgery on the quality of life of early breast cancer patients. Eur J Surg Oncol. 1986 Dec;12(4):337–342. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES